Athersys (ATHX) Prices 22.25M Share Common Offering at $2.25/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/10/2026
- S&P 500, Dow futures attempt recovery ahead of inflation report
- Oil surges 6%, Brent and US crude both surpass $100 on more tanker attacks
- Analysts split on Apple after foldable iPhone Duo debut
- JPMorgan upgrades Meta on AI models and agents, sees 'meaningful headroom'
- HSBC lifts Novartis, downgrades Amgen in biopharma catalyst review
- S&P 500 ends down as oil tops $100 per barrel
- White House copper tariff plan stalls amid affordability concerns, sources say
- Trump promises $5,000 payout to U.S. adults if Republicans win election
- Crude Inventory 0.4M Barrels Last Week - EIA
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
After-Hours Stock Movers 04/15: (RCUS) (AM) (BBBY) Higher; (ATHX) (CALA) (LAKE) Lower (more...)
April 15, 2020 6:03 PM EDTToday's After-Hours Stock Movers
Arcus Biosciences (NYSE: RCUS) 47.5% HIGHER; Gilead (NASDAQ: GILD) is considering acquiring a stake in Arcus Biosciences (NYSE: RCUS), according to Bloomberg, citing people familiar with the matter.
Antero Midstream (NYSE: AM) 16.8% HIGHER; said first quarter 2020 dividend is unchanged as compared to the fourth quarter of 2019.
Bed Bath & Beyond (NASDAQ: BBBY) 14.4% HIGHER; reported Q4 EPS... More
Athersys (ATHX) intends to offer for sale $50 million of shares of its common stock
April 15, 2020 4:28 PM EDTAthersys, Inc. (NASDAQ: ATHX) (Athersys) announced today that it intends to offer for sale $50 million of shares of its common stock, par value $0.001 per share (Common Stock), in an underwritten public offering. In addition, Athersys expects to grant the underwriters a 30-day option to... More
Pre-Open Movers 04/15: (JBLU) (UEPS) (ATHX) Higher; (CVA) (IVZ) (ILMN) Lower (more...)
April 15, 2020 9:30 AM EDTToday's Pre-Open Stock Movers
Covanta Holding (NYSE: CVA) 12.1% LOWER; Withdraws 2020 Guidance. Stifel downgraded Covanta (NYSE: CVA) from Buy to Sell with a price target of $6.50 (from $17.50).
JetBlue Airways (NASDAQ: JBLU) 9% HIGHER; To particulate in Treasury payroll support program
Invesco (NYSE: IVZ) 7.5% LOWER; Citi downgraded from Neutral to Sell with a price target of $5.50 (from... More
Athersys (ATHX) Reports FDA Approval to Begin Phase 2 Trial Evaluating MultiStem Cell Therapy in Trauma Patients
April 15, 2020 6:01 AM EDTAthersys, Inc. (NASDAQ: ATHX) announced today that the U.S. Food and Drug Administration (FDA) has authorized an Investigational New Drug (IND) application to initiate a Phase 2 clinical trial evaluating Athersys MultiStem® cell therapy for early treatment of traumatic injuries and the subsequent complications that result following severe trauma. Memorial Hermann-Texas Medical Center in Houston, Texas, one of the busiest Level 1 trauma centers in the United States, intends to conduct the trial. The study represents another important application of the companys MultiStem cell therapy in the critical care area, targeting the severe inflammatory responses... More
